The Effect of Growth Hormone in Very Young Girls With Turner Syndrome

Eli Lilly and Company100 enrolled

Overview

This study investigated the effect of growth hormone on the growth of infants and toddlers with Turner syndrome during 2 years of treatment with growth hormone. This was compared with the growth of infants and toddlers with Turner syndrome who did not receive any growth hormone treatment. The overall aim was to prevent the growth failure usually seen during this period. The study also looked at middle ear disease, hearing problems, and cognitive and behavioral development.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Turner Syndrome

Interventions

SomatropinDRUG

Eligibility

Sex: FEMALEMin age: 9 MonthsMax age: 4 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Karyotype-proven Turner syndrome that included a documented abnormality of the short arm of an X chromosome. * At least 9 months of age and not greater than 4 years of age. * Normal values for age for hemoglobin, thyroid stimulating hormone (TSH) and urinalysis (office dipstick is adequate), performed prior to study entry. * If there was a known history of hypothyroidism, then adequate thyroid hormone replacement must have been taken for at least 6 months prior to study entry. Exclusion Criteria: * Current or previous treatment with any therapy that may have directly influenced growth, including growth hormone, growth hormone-releasing hormone, estrogens and anabolic steroids such as oxandrolone. This included previous completion of, or withdrawal from, this study or any other study investigating therapeutic uses of growth hormone or growth hormone-releasing hormone. * Chronic treatment with systemic glucocorticoids in supra-physiological doses. * Treatment with potential growth-influencing medications such as methylphenidate (Ritalin), pemoline (Cylert), and amphetamines, at, or within 3 months prior to, study entry. * Presence of any Y chromosome component in the karyotype if gonads were in situ. Subjects whose karyotype contained Y chromatin, but who had undergone gonadectomy, were eligible to enter the study. * Presence of any additional known autosomal abnormality.

Locations (10)

Outcomes

Primary Outcomes

Height at the end of two years in the study.

Secondary Outcomes

Middle ear problems assessed every 4 months

Hearing problems assessed annually

Cognitive and behavioral development assessed annually

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Los Angeles, California, United States

Stanford, California, United States

Denver, Colorado, United States

Hartford, Connecticut, United States

Chicago, Illinois, United States

Indianapolis, Indiana, United States

Lexington, Kentucky, United States

Kansas City, Missouri, United States

Philadelphia, Pennsylvania, United States

Seattle, Washington, United States